The FDA is making Valneva wait. Two weeks from the original deadline, the agency has pushed back its decision on whether to approve Valneva’s chikungunya virus vaccine candidate by three months.

March 20 (Reuters) - French biotech company Valneva VLS.PA on Wednesday raised its product sales guidance and said it now expects revenues of between 170 million euros and 190 million euros ($184.72 ...

Add Yahoo as a preferred source to see more of our stories on Google. Illustration shows Valneva logo (Reuters) -France's Valneva on Wednesday said it expects to nearly double its annual product sales ...

Valneva’s plans to establish its COVID-19 vaccine as a booster to Pfizer and BioNTech’s Comirnaty have taken a blow, with a clinical trial of the shot eliciting “only a marginally increased ...

The stage is set for a defining period. Valneva's strategic pivot has garnered investor confidence, and its financial runway is secure. All eyes are now on the scientific data expected in the coming ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo of French-Austrian biotech firm Valneva is seen outside their headquarters in Vienna, Austria, December 16, ...

The U.S. health officials have recommended a pause in the use of French biotech Valneva’s (NASDAQ:VALN) chikungunya vaccine Ixchiq for those aged 60 years and older amid an ongoing safety review over ...

Valneva SE (NASDAQ:VALN), on Monday, sold the FDA Priority Review Voucher (PRV) for $103 million (€95 million). The company was awarded a tropical disease PRV in November 2023 following the FDA ...